SENSEX NIFTY

Arun Chandavarkar

Dec 10, 2015 at 10:00 | Source: CNBC-TV18
Speaking to CNBC-TV18, Dr Arun Chandavarkar, CEO & Joint MD, Biocon says that the company is also looking to introduce its biosimilars and insulin portfolio in the UAE.
Apr 25, 2014 at 09:41 | Source: Moneycontrol.com
Biopharmaceutical major Biocons consolidated net profit (adjusted for one-off item) for the March quarter jumped 140 percent year-on-year to Rs 113 crore, and revenues grew 15 percent to Rs 746 crore.
Apr 23, 2008 at 19:02
Biocon Group Revenues Rs 1,090cr, EBITDA Rs 335cr, PAT Rs 225cr. Earnings per share at Rs 22.5 for the year.
Apr 19, 2007 at 16:01
Biocon has come out with its fourth quarter results. The company posted consolidated net profit of Rs 60.7 crore (Rs 607 million) in fourth quarter versus Rs 48 crore (Rs 480 million) in corresponding quarter of previous year.
Apr 19, 2007 at 10:40
Biocon's FY 2006-07 performance shows healthy growth. Revenues Rs 990 cr, EBITDA Rs 287cr, PAT Rs 200cr
Apr 19, 2007 at 10:39
Biocon has come out with its fourth quarter results. The company posted consolidated net profit of Rs 60.7 crore (Rs 607 million) in fourth quarter versus Rs 48 crore (Rs 480 million) in corresponding quarter of previous year.
Messages on Arun Chandavarkar »

biomagic

New Member

14 Followers

Biocon  

Biocon CEO & Joint MD Arun Chandavarkar termed the submission as "an important milestone of Biocon and Mylan`s joint global biosimilars program" It "demonstrates our commitment to provide access to high-quality and affordable biologics to patients across the globe. Cancer patients in India

9.12 PM Nov 10th 2016

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.